Gocovri Before FDA as Possible Bedtime Therapy for ‘Off’ Time in Parkinson’s

Gocovri Before FDA as Possible Bedtime Therapy for ‘Off’ Time in Parkinson’s
The U.S. Food and Drug Administration (FDA) has agreed to review Adamas Pharmaceutical’s application asking that oral Gocovri (amantadine) also be approved to treat off episodes in Parkinson’s disease patients using levodopa. An FDA decision on  the company’s supplemental new drug application (sNDA) is expected by Feb. 1, 2021. This medication is currently the only treatment approved in the U.S. for dyskinesia — involuntary, jerky movements — in ... read more
Source: Parkinson’s News TodayPublished on 2020-06-08By Patricia Inacio, PhD